Innate Pharma (IPHA) Return on Equity (2020 - 2025)

Innate Pharma (IPHA) has 6 years of Return on Equity data on file, last reported at 0.11% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity rose 15.0% year-over-year to 0.11%; the trailing twelve-month figure through Dec 2025 stood at 0.11% (up 15.0% YoY), and the FY2022 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.11%, up from 0.15% in the prior quarter.
• Across five years, Return on Equity topped out at 0.11% in Q4 2025 and bottomed at 0.15% in Q2 2025.
• The 5-year median for Return on Equity is 0.01% (2021), against an average of 0.01%.
• Peak annual rise in Return on Equity reached 15 bps in 2025, while the deepest fall reached 14 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2021, then soared by 98 bps to 0.0% in 2022, then tumbled by 1122 bps to 0.0% in 2023, then tumbled by 3264 bps to 0.04% in 2024, then surged by 348 bps to 0.11% in 2025.
• The last three Return on Equity figures came in at 0.11% (Q4 2025), 0.15% (Q2 2025), and 0.04% (Q4 2024), per Business Quant data.

Peer Comparison